Elekta Has Received Approval For Elekta Compact™ In China

Main Category: Radiology / Nuclear Medicine
Article Date: 14 Jan 2009 - 0:00 PST

email to a friend   printer friendly   view / write opinions   rate article

Elekta (STO:EKTAB) has received approval from the Chinese authority SFDA (State Food and Drug Administration) to sell its linear accelerator Elekta Compact™ in China.

Elekta Compact™ is a competitive linear accelerator for high quality conventional radiotherapy, configured for countries in need of rapid build-up of additional treatment capacity. Elekta Compact is based on a combination of technology from Elekta and from the product platform developed by the Chinese company BMEI, which Elekta acquired in 2006.

There is a large potential for Elekta Compact in China, where there is shortage of good cancer treatment. The number of linear accelerators is less than one per million inhabitants and a large part of the existing systems needs to be replaced. Further, Elekta Compact is the ideal treatment system when replacing existing Cobalt units as the platform allows for further growth and expansion, says Tomas Puusepp, President and CEO of Elekta.

In May 2008 Elekta received SFDA approval to export Elekta Compact outside China and in June 2008 Elekta completed the process of adding CE marking, allowing Elekta Compact to be marketed in Europe, Latin America and Asia.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated state of the art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb.

Elekta Group